Last €2.08 EUR
Change Today +0.021 / 1.02%
Volume 47.0K
COX On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
Frankfurt
As of 9:08 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Drakkar 2 - Bât D

2405 route des Dolines

CS 10313

Sophia Antipolis, 06906

France

Phone: 33 4 97 24 53 00

Fax: 33 4 97 24 53 99

Nicox SA, a research pharmaceutical company, engages in the research and development of nitric oxide-donating drugs with superior efficacy and safety profiles in the inflammation, pain and cardiovascular therapeutic areas. The company seeks to commercialize its products through partnerships and co-development agreements where it maintains future marketing rights for specialist products. NicOx has retained all marketing rights for the U.S. and Asia in addition to co-marketing rights in the European Union and EFTA. Products NCX 4016: NCX 4016 is a novel anti-thrombotic and vascular anti-inflammatory nitric oxide-donating agent, which is in phase II clinical trials for the treatment of the symptoms of peripheral arterial obstructive disease (PAOD). HCT 3012: HCT 3012 is the lead compound in a new class of analgesic and anti-inflammatory drugs, known as CINODs (COXInhibiting Nitric Oxide Donators) designed for the treatment of osteoarthritis. NicOx has planned a comparative clinical study to evaluate the effects of HCT 3012 on arterial blood pressure in patients with mild essential hypertension. NCX 701: NCX 701 is a nitric oxide-donating analgesic, is in development for acute pain management. The compound is in phase II clinical development. NCX 1510: NCX 1510 is a nitric oxide-donating drug successfully selected from the joint research program with Biolipox to advance into clinical development for the treatment of allergic rhinitis. In June 2004, NicOx’ partner, Biolipox AB, announced successful phase IIa clinical trial results in allergic rhinitis with NCX 1510. NCX 1000: NCX 1000 is being developed under a co-development and license agreement with Axcan Pharma for the treatment of chronic liver diseases including portal hypertension and Hepatitis C. Several animal studies have already shown the pharmacological effects of NCX 1000 on portal pressure. HCT 1026: HCT 1026, a patented nitric oxide-donating derivative of flurbiprofen, is in clinical development for the treatment of Alzheimer’s Disease. In April 2004, NicOx announced that HCT 1026, a novel NO-donating derivative of flurbiprofen, was found to significantly reduce beta-amyloid deposition in the brain of a mouse model of Alzheimer’s Disease, the most common form of dementia in the elderly. NCX 1020: NCX 1020, a nitric oxide-donating derivative of budesonide is in phase I/IIa clinical trials for the treatment of asthma. NCX 1020 is a new class of inhaled steroids targeted at the treatment of severe respiratory diseases, such as asthma and Chronic Obstructive Pulmonary Disease (COPD). NCX 1022: NicOx and its partner Ferrer are conducting a program of synthesis and screening of a series of potency NOdonating steroids to identify a new lead development candidate with maximum commercial potential to take into an accelerated development program. The company received positive results from a phase IIa trial for NCX 1022, an ointment for the treatment of seborrheic dermatitis. NCX 1022 is the prototype nitric oxide-donating steroid and is a derivative of the steroid hydrocortisone. Strategic Collaborations The company in collaboration with Spain's Ferrer Pharmaceuticals has developed NCX 1022, its anti-inflammatory dermatology product. The company’s corporate partners include: Axcan Pharma Inc.; Biolipox AB; Merck & Co., Inc.; Ferrer Grupo; and Pfizer Inc. Biolipox AB: In 2001, NicOx signed a research and co-development agreement for a novel class of nitric oxide-donating respiratory therapeutics with the Swedish research-based company Biolipox. Axcan Pharma, Inc.: The company has partnership with Axcan Pharma, Inc for the positive phase I clinical results, development of NCX 1000 is advancing into phase II clinical trials for the treatment of portal hypertension, a life threatening complication of chronic liver disease. In 2002, NicOx signed a codevelopment and license agreement for NCX 1000 with Axcan, a North American specialty pharmaceutical company in the gastro-enterology field. Merck & Co., Inc.: The company has a research collaboration with Merck progressed in evaluating the therapeutic of a series of NicOx’ products. NicOx synthesized a series of nitric oxide-donating compounds which have entered a pre-clinical evaluation program in the laboratories of Merck and of NicOx. In August 2003, NicOx signed a research evaluation agreement with Merck to evaluate selected nitric oxide-donating compounds under NicOx’ intellectual property rights. Ferrer Grupo: In April 2004, NicOx signed a licensing and co-development agreement with Ferrer Grupo for the research, development and marketing of certain new steroid derivatives for the treatment of dermatological diseases in selected markets. Ferrer has marketing rights for the European Union (including EFTA), Latin America and French-speaking Africa (including Morocco and Algeria) and Egypt. NicOx retains rights to co-market products directly in the European Union and EFTA. NicOx retains all rights for the U.S. and Asia. A joint development committee is coordinating and overseeing all research and development activities. Pfizer, Inc.: In August, 2004, NicOx signed a research, option, development and licensing agreement with Pfizer, Inc. related to selected proprietary NicOx nitric oxidedonating compounds. Under the agreement, NicOx grants Pfizer an option to acquire an exclusive worldwide license covering early-stage nitric oxide-donating compounds in an undisclosed field. Significant Events NicOx SA and Topigen Pharmaceuticals, Inc. have initiated a Phase II trial of TPI 1020, an anti-inflammatory drug candidate developed by NicOx for the treatment of chronic obstructive pulmonary disease (COPD). TPI 1020 is an inhaled nitric oxide-donating derivative of budesonide, a corticosteroid marketed by AstraZeneca plc, of London, under the name ofPulmicort. History Nicox SA was founded in 1996.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COX:FP €2.08 EUR +0.021

COX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COX.
View Industry Companies
 

Industry Analysis

COX

Industry Average

Valuation COX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NICOX SA, please visit www.nicox.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.